Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

Olutasidenib

🥰Excellent
Catalog No. T16384Cas No. 1887014-12-1
Alias FT-2102

Olutasidenib (FT-2102) is under the study in the treatment of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Olutasidenib is a highly effective, brain penetrant, and selective inhibitor of the mutant Isocitrate dehydrogenase 1 (IDH1) (IC50: 21.2 nM and 114 nM for IDH1- R132H and IDH1- R132C, respectively).

Olutasidenib

Olutasidenib

🥰Excellent
Purity: 98.57%
Catalog No. T16384Alias FT-2102Cas No. 1887014-12-1
Olutasidenib (FT-2102) is under the study in the treatment of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Olutasidenib is a highly effective, brain penetrant, and selective inhibitor of the mutant Isocitrate dehydrogenase 1 (IDH1) (IC50: 21.2 nM and 114 nM for IDH1- R132H and IDH1- R132C, respectively).
Pack SizePriceAvailabilityQuantity
1 mg$56In Stock
5 mg$172In Stock
10 mg$278In Stock
25 mg$513In Stock
50 mg$747In Stock
100 mg$1,050In Stock
200 mg$1,390In Stock
1 mL x 10 mM (in DMSO)$188In Stock
Bulk & Custom
Add to Cart
Questions
View More

Related Compound Libraries of "Olutasidenib"

Select Batch
Purity:98.57%
Contact us for more batch information
Resource Download
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Product Introduction

Bioactivity
Description
Olutasidenib (FT-2102) is under the study in the treatment of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Olutasidenib is a highly effective, brain penetrant, and selective inhibitor of the mutant Isocitrate dehydrogenase 1 (IDH1) (IC50: 21.2 nM and 114 nM for IDH1- R132H and IDH1- R132C, respectively).
Targets&IC50
IDH1 (R132C):114 nM (IC50), IDH1 (R132H):21.2 nM (IC50)
In vitro
Olutasidenib is highly selective for IDH1 isoforms, showing no appreciable inhibition against wild-type IDH1 (> 20 μM) and IDH2 mutants (R172K and R140Q: both > 20 μM). Olutasidenib effectively suppresses 2-HG production by multiple IDH1-R132 mutants (R132H, R132C, R132G, R132L), displaying Olutasidenib (FT-2102) could be efficacious against most IDH1-R132 mutant-expressing tumors [2].
In vivo
In HCT116-IDH1-R132H/+ xenograft bearing female BALB/c Nude mice, Olutasidenib (three oral doses (12.5, 25, and 50 mg/kg) in 12-hour intervals) shows effective anti-tumor activity [2].
AliasFT-2102
Chemical Properties
Molecular Weight354.79
FormulaC18H15ClN4O2
Cas No.1887014-12-1
SmilesC[C@H](Nc1ccc(C#N)n(C)c1=O)c1cc2cc(Cl)ccc2[nH]c1=O
Relative Density.1.42 g/cm3 (Predicted)
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
Solubility Information
DMSO: 122 mg/mL (343.87 mM), Sonication is recommended.
Solution Preparation Table
DMSO
1mg5mg10mg50mg
1 mM2.8186 mL14.0928 mL28.1857 mL140.9284 mL
5 mM0.5637 mL2.8186 mL5.6371 mL28.1857 mL
10 mM0.2819 mL1.4093 mL2.8186 mL14.0928 mL
20 mM0.1409 mL0.7046 mL1.4093 mL7.0464 mL
50 mM0.0564 mL0.2819 mL0.5637 mL2.8186 mL
100 mM0.0282 mL0.1409 mL0.2819 mL1.4093 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify
For Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
%Tween 80
%ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy Olutasidenib | purchase Olutasidenib | Olutasidenib cost | order Olutasidenib | Olutasidenib chemical structure | Olutasidenib in vivo | Olutasidenib in vitro | Olutasidenib formula | Olutasidenib molecular weight